Abstract: Objective To investigate the expression of hMLH1, hMSH2, hMSH6 in cervical cancer patients and its effect on prognosis.Methods We collected 90 paraffin-embedded specimens from patients with pathological cervical cancer from January 2011 to January 2013. Immunohistochemistry was used to detect the expression of hMLH1, hMSH2, and hMSH6 in cervical cancer tissues.The relationship between the expression status of mismatch repair (MMR) protein and its clinicopathological features and prognosis was analyzed.Results The missing rate of MMR expression was 21. 11% (21/90). There were significant differences in staging, differentiation and lymph node metastasis between patients withMMR-expressed and normal MMR (P<0.05). MMR deletions were more common in patients with moderately-differentiated, stage I, and lymph node metastases were more difficult to occur. The 5-year disease-free survival rate in the deficient mismatch repair (d MMR) group was 61.90% (13/21), which was significantly higher than that in the (proficient mismatch repair) pMMR group (40.58%, 28/69). The difference was statistically significant (χ²= 4.967, P=0.026). The 5-year overall survival rate in the dMMR group was 76. 19% (16/21), which was higher than that in the pMMR group 52.17% (36/69) . The difference was statistically significant (χ²= 4.834, P=0.028). MMR status, staging, differentiation, and lymph node metastasis were independent factors that affected the disease-free survival and overall survival of patients.Conclusions Loss of MMR expression is more common in patients with more moderately-differentiated and stage I patients. and lymph node metastasis is more difficult to occur in patients withMMR deletions. MMR status is an independent factor that affects the prognosis of cervical cancer patients. Patients with missing MMR expression had a better prognosis than patients with normal MMR expression.